339 related articles for article (PubMed ID: 35111155)
1. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
Shi AP; Tang XY; Xiong YL; Zheng KF; Liu YJ; Shi XG; Lv Y; Jiang T; Ma N; Zhao JB
Front Immunol; 2021; 12():785091. PubMed ID: 35111155
[TBL] [Abstract][Full Text] [Related]
2. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Qian W; Zhao M; Wang R; Li H
J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
[TBL] [Abstract][Full Text] [Related]
3. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.
Zuo D; Zhu Y; Wang K; Qin Y; Su Y; Lan S; Li Y; Dong S; Liang Y; Feng M
Biomed Pharmacother; 2024 Jun; 175():116782. PubMed ID: 38776682
[TBL] [Abstract][Full Text] [Related]
4. The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy.
Mariuzza RA; Shahid S; Karade SS
J Biol Chem; 2024 May; 300(5):107241. PubMed ID: 38556085
[TBL] [Abstract][Full Text] [Related]
5. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.
Ming Q; Celias DP; Wu C; Cole AR; Singh S; Mason C; Dong S; Tran TH; Amarasinghe GK; Ruffell B; Luca VC
Nat Immunol; 2022 Jul; 23(7):1031-1041. PubMed ID: 35761082
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.
Yang C; Qian Q; Zhao Y; Huang B; Chen R; Gong Q; Ji H; Wang C; Xia L; You Z; Zhang J; Chen X
Front Immunol; 2023; 14():1112672. PubMed ID: 36993960
[TBL] [Abstract][Full Text] [Related]
7. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L
Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966
[TBL] [Abstract][Full Text] [Related]
8. Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1.
Zhang WT; Liu TT; Wu M; Chen XC; Han L; Shi ZZ; Li YY; Li XY; Xu HX; Gong LK; Xu PH; Geng Y
Acta Pharmacol Sin; 2021 Nov; 42(11):1921-1929. PubMed ID: 33633363
[TBL] [Abstract][Full Text] [Related]
9. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.
Ruffo E; Wu RC; Bruno TC; Workman CJ; Vignali DAA
Semin Immunol; 2019 Apr; 42():101305. PubMed ID: 31604537
[TBL] [Abstract][Full Text] [Related]
11. The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating
Tang XY; Xiong YL; Shi AP; Sun Y; Han Q; Lv Y; Shi XG; Frattini M; Malhotra J; Zheng KF; Liu YJ; Jiang T; Ma N; Zhao JB
Transl Lung Cancer Res; 2022 Mar; 11(3):404-419. PubMed ID: 35399566
[TBL] [Abstract][Full Text] [Related]
12. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy.
Du H; Yi Z; Wang L; Li Z; Niu B; Ren G
Int Immunopharmacol; 2020 Jan; 78():106113. PubMed ID: 31841754
[TBL] [Abstract][Full Text] [Related]
13. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
[TBL] [Abstract][Full Text] [Related]
14. FGL1-LAG3 axis impairs IL-10-Producing regulatory T cells associated with Systemic lupus erythematosus disease activity.
Chen K; Li X; Shang Y; Chen D; Qu S; Shu J; Zhang M; Wang Z; Huang J; Wu M; Ming S; Wu Y
Heliyon; 2023 Oct; 9(10):e20806. PubMed ID: 37916085
[TBL] [Abstract][Full Text] [Related]
15. Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential.
Liu XH; Qi LW; Alolga RN; Liu Q
Int J Biol Sci; 2022; 18(1):292-300. PubMed ID: 34975333
[TBL] [Abstract][Full Text] [Related]
16. The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif.
Aigner-Radakovics K; De Sousa Linhares A; Salzer B; Lehner M; Izadi S; Castilho A; Pickl WF; Leitner J; Steinberger P
Sci Signal; 2023 Oct; 16(805):eadg2610. PubMed ID: 37788323
[TBL] [Abstract][Full Text] [Related]
17. Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples.
Liu Q; Qi Y; Zhai J; Kong X; Wang X; Wang Z; Fang Y; Wang J
Front Immunol; 2021; 12():599207. PubMed ID: 34267742
[TBL] [Abstract][Full Text] [Related]
18. A Double-Antibody Sandwich ELISA for Sensitive and Specific Detection of Swine Fibrinogen-Like Protein 1.
Zhang X; Zhu H; Zheng X; Jiao Y; Ning L; Zhou EM; Mu Y
Front Immunol; 2021; 12():670626. PubMed ID: 33968077
[TBL] [Abstract][Full Text] [Related]
19. Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction.
Abdel-Rahman SA; Zhang L; Gabr MT
SLAS Discov; 2023 Jun; 28(4):188-192. PubMed ID: 37121273
[TBL] [Abstract][Full Text] [Related]
20. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer.
Li JJ; Wang JH; Tian T; Liu J; Zheng YQ; Mo HY; Sheng H; Chen YX; Wu QN; Han Y; Liao K; Pan YQ; Zeng ZL; Liu ZX; Yang W; Xu RH; Ju HQ
Nat Commun; 2023 Oct; 14(1):6690. PubMed ID: 37872170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
